Chemotherapy
Foundation Symposium XIX
"Innovative Cancer Therapy for Tomorrow" Jointly
sponsored by the Page & William Black Post-Graduate School of
the Mount Sinai School of Medicine and the Chemotherapy Foundation
('01)
Breakfast Presentation
A:
WEEKLY PAXLITAXEL AND WEEKLY DOCETAXEL
AS SALVAGE THERAPY IN METASTATIC
BREAST CANCER |
Hans-Joachim Luck, M.D. |
| INTRODUCTION |
Ezra Greenspan, M.D. |
MORNING SESSION A:
HEMATOLOGIC MALIGNANCIES
Moderators: Janice L. Gabrilove, M.D., James F. Holland, M.D., Janet
Cuttner, M.D.
| THERAPEUTIC STRATEGIES IN CLL |
Janice l. Gabrilove, M.D. |
| ADVANCES IN PROMYELOCYTIC LEUKEMIA |
Samuel Waxman, M.D. |
| INTERFERONE PLS ARA C AND OTHER COMBINATIONS
IN CML |
Hagop Kantarjian, M.D. |
| NOVEL BUT NOT MORE AGGRESSIVE CHEMOTHERAPY:
THE RATIONALE FOR NONMYELOABLATIVE STEM CELL TRANSPLANTATION |
Shimon Slavin, M.D. |
| CAMPATH IH THERAPY IN CLL PATIENTS WHO FAILED
ON FLUDARABINE |
Kanti R. Rai, M.D. |
| TARGETED THERAPY OF CUTANEOUS T-CELL LYMPHOMA |
C.F. LeMaistre, M.D. |
| CLINICAL TRIALS WITH SD-01 AS
A GCSF CONGENER TO CHEMOTHERAPY |
Jeffrey Crawford, M.D. |
| CURRENT THERAPY OF WALDENSTROM'S
MACROGLOBULINEMIA |
Donna Weber, M.D. |
| LIPOSOMAL DAUNORUBICIN THERAPY
FOR MULTIPLE MYELOMA |
Ann Mohrbacher, M.D. |
| LIPOSOMAL DAUNORUBICIN AND CVP
FOR LYMPHOMAS |
Ian W. Flinn, M.D. |
Lunch Presentation A:
| ROLE OF TAXANE-DOXORUBICIN COMBINATIONS
IN MANAGEMENT OF BREAST CANCER |
Jean-Marc A. Nabholtz, M.D. |
AFTERNOON SESSION A:
Moderators: Edward P. Ambinder, M.D., Steve Itzkowitz,
M.D., Lewis R. Silverman, M.D.
| GI CANCERS: GEMCITABINE AND IRINOTECAN
IN ADVANCED GI CANCER |
Eileen O'Reilly, M.D. |
| IRINOTECAN-BASED COMBINATION THERAPY IN FIRST-LINE
AND ADJUVANT TREATMENT OF COLON CANCER |
Leonard B. Saltz, M.D. |
| GEMCITABINE AS MODCULATOR OF 5 FU/LEUCOVORIN
IN COLON CANCER |
Stefan Madajewicz, M.D. |
| ORAL AGENTS IN TREATMENT OF COLORECTAL CANCER |
Paulo M. Hoff, M.D. |
| ADJUVANT THERAPY OF COLON CANCER:
THE NSABP EXPERIENCE |
Norman Wolmark, M.D. |
PHASE I/II STUDY OF CONCURRENT
RADIATION AND TWICE-WEEKLY GEMCITABINE IN
UNRESECTABLE PANCREATIC CANCER |
A. William Blackstock, M.D. |
| RUBITECAN (9-NITRO CAMPTOTRECIN
RFS 2000) THERAPY OF PANCREATIC CANCER |
Howard A. Hochster, M.D. |
| CPT-11 AND CISPLATIN IN METASTATIC
GASTRIC CANCER |
Jaffer A. Ajani, M.D. |
| TRIMETRAXATE AS A BIOCHEMICAL
MODULATOR OF 5-FU IN COLORECTAL CANCER |
Cornelis J.A. Punt, M.D., Ph.D. |
| INTRADOSE INJECTABLE GEL IN TREATMENT
OF HEPATIC TUMORS |
Philip A. Johnson, M.D. |
| EDROCOLAMAB (panorex, maB 17-1A):
UPDATE OF SAFETY INFORMATION FROM TWO RANDOMIZED TRIALS |
Alan M. Keller, M.D. |
| RECENT ADVANCES IN PATIENTS WITH
UROTHELIAL CANCER |
Dean Bajorin, M.D. |
| VALRUBICIN IN BCG-REFRACTORY CARCINOMA
"IN SITU" OF THE BLADDER |
Robert R. Bahnson, M.D. |
| CONCOMITANT CHEMORADIOTHERAPY
WITH GEMCITABINE, 5-FU & PACLITAXEL IN HEAD & NECK CANCER |
Keith Schulman, M.D. |
| RECENT ADVANCES IN THE TREATMENT
OF NON-HODGKIN'S LYMPHOMA |
John D. Hainsworth, M.D. |
MORNING SESSION B:
Moderators: Edward P. Ambinder, M.D., Steven M. Fruchtman,
M.D., Michael A.Goldsmith, M.D.
| ANGIOGENESIS SESSION: MULTIPLE
MYELOMA: THERAPEUTIC OPTIONS IN 2000 |
Robert A. Kyle, M.D. |
| THALIDOMIDE AS A DISEASE MODIFIER IN MYELOMA
THERAPY |
Bart Barlogie, M.D. |
| DEVELOPMENT OF ANGIOSTATIN & ENDOSTATIN |
Michael S. O'Reilly, M.D. |
| ANGIOGENESIS INHIBITOR SU5416
WITH 5 FY/LEUCOVORIN IN METASTATIC COLORECTAL CANCER |
Lee S. Rosen, M.D. |
| THALIDOMIDE IN HIGH GRADE MALIGNANT BRAIN
NEOPLASMS |
Michael L Gruber, M.D. |
| TREATMENT OF ADVANCED RENAL CELL CARCINOMA
WITH THALIDOMIDE |
Tim Eisen, M.B., Ph.D. |
| CARTILAGE-DERIVED ANGIOGENIC AGENTS |
Gerard Batist, M.D. |
| DEVELOPMENT OF PKC/CDK INHIBITORS FOR CANCER
THERAPY |
Gary K. Schwartz, M.D. |
| ALTERATION OF THE HER-2/neu GENE IN BREAST
CANCER: DIAGNOSTIC AND THERAPEUTIC IMPLICATIONS |
Dennis J. Slamon, M.D. |
| TAXOL-CARBOPLATIN/HERCEPTIN IN METASTATIC
DISEASE |
Nicholas J. Robert, M.D. |
Lunch Presentation B:
| TOMUDEX IN COLORECTAL CANCER |
Joseph R. Bertino, M.D. |
| TOMUDEX IN COLORECTAL CANCER |
Gary K. Schwartz, M.D. |
| TOMUDEX IN COLORECTAL CANCER |
Philippe Rougier, M.D. |
| TOMUDEX IN COLORECTAL CANCER |
Jean A. Maroun, M.D. |
| DISCUSSION |
|
AFTERNOON SESSION B:
Moderators: Ezra M. Greenspan, M.D., Larry Norton, M.D., George
Raptis, M.D.
| BREAST CANCER: TAXOL VS. FAC IN
TRIAL OF NEOADJUVANT CHEMOTHERAPY IN EARLY BREAST CANCER |
Joseph R. Bertino, M.D. |
| NEW DIRECTIONS IN THE NEOADJUVANT
CHEMOTHERAPY OF BREAST CANCER |
Mark Graham, M.D. |
| SERMS: CONCEPT TO REALITY FOR THE PREVENTION
OF BREAST CANCER |
V. Craig Jordan, Ph.D., D.Sc. |
| BLIND-SPOTS IN THE CLINICAL INVESTIGATION
OF BREAST CANCER THERAPY |
Ezra M. Greenspan, M.D. |
| INTESTINAL TREFOIL FACTOR (ITF): PROMISE FOR
COLON CANCER GENE THERAPY |
Steven K. Itzkowitz, M.D. |
| MODULATING TAXANES: PSC 833, DPPE AND OTHER
AGENTS |
Anne Hamilton, M.D. |
| VX-710 (INCEL) TO OVERCOME DRUG RESISTANCE
IN CHEMOTHERAPY-REFRACTORY SOLID TUMOR PATIENTS |
George D. Demetri, M.D. |
| COMBINED TAXANE THERAPY: WEEKLY
PACLITAXEL PLUS DOCETAXLE |
Jacob Lokich, M.D. |
| GEMCITABINE PLUS CISPLATIN "REPEATING DOUBLET"
THERAPY IN RELAPSED OVARIAN CANCER |
Robert A. Nagourney, M.D. |
| SEQUENTIAL COUPLETS OF CISPLATIN/TOPOTECAN
AND CISPLATIN/PACLITAXEL AS PRIMARY THERAPY FOR ADVANCED OVARIAN
CANCER |
Paul J. Hoskins, M.D. |
| OVAREX MAB - A LOW DOSE XENOTYPIC ANTIBODY
APPROACH TO OVARIAN CANCER IMIMUNOTHERAPY |
Jeffrey Bloss, M.D. |
| CHEMORADIATION FOR CERVICAL CARCINOMA |
Charles W. Whitney, M.D. |
Breakfast Presentation C:
OXALIPLATIN: NEW TREATMENT OPTIONS
IN ADVANCEDCANCER
|
Mace L. Rothenberg, M.D. |
MORNING SESSION C:
Moderators: Anna C. Ferrari, M.D., A. Philippe Chahanian, M.D.
PROSTATE CANCER MINISYMPOSIUM:
IMMUNOLOGIC THERAPY WITH GMCSF OR DENDRITICCELLS
|
Eric J. Small, M.D. |
| DEVELOPMENT OF THERAPY FOR ADVANCED PROSTATE
CANCER |
Christopher J. Logothetis, M.D. |
| CHEMOTHERAPY FOR HORMONE REFRACTORY PROSTATE
CANCER |
Daniel P. Petrylak, M.D. |
| ANGIOGENETIC BIOMOEDULATION IN TREATMENT OF
METASTATIC PROSTATE CANCER |
William Figg, M.D. |
| PILOT STUDY OF WEEKLY VINORELBINE & PACLITAXEL
FOR HORMONE REFRACTORY PROSTATE CANCER |
Roger B. Cohen, M.D. |
| LUNG CANCER MINISYMPOSIUM: GEMCITABINE
& TAXOTERE COMBINATIONS IN NSCLC |
James B. Rigas, M.D. |
| CONCURRENT TAXOL/CARBOPLATIN &
RADIOTHERAPY IN STAGE III NSCLC |
Hak Choy, M.D. |
| PHASE I/II TRIAL OF CARBOPLATIN,
PACLITAXEL AND CPT-11 IN ADVANCED NSCLC |
Mark A. Socinski, M.D. |
| WEEKLY CHEMOTHERAPY: RESULTS WITH
GEMCITABINE, TAXOTERE AND NAVELBINE IN NSCLC |
Howard A. Burris III, M.D. |
| TAXOL AND HYCAMTIN IN SCLC |
Samuel A. Jacobs, M.D. |
| MESOTHELIOMA: IS IT TREATABLE? |
A. Philippe Chahanian, M.D. |
Lunch Presentation C:
NOVEL REGIMENS FOR SCLC
|
Roman Perez-Soler, M.D.
Rogerio Lilenbaum, M.D. |
AFTERNOON SESSION C:
Moderators: Jonathan D. Licht, M.D., Lloyd Mayer, M.D., Seymour
M. Cohen,M.D.
| PHASE II GLIOMA TRIALS
WITH COMBINATIONS AND NEW AGENTS |
Victor A. Levin, M.D. |
| POTENTIATION OF TAXOL PENETRATION
INTO BRAIN TUMORS TO TAMOXIFEN |
Robert L. Fine, M.D. |
| AMIFOSTINE AS MODULATOR OF ESOPHAGITIS IN
CHEMORADIOTHERAPY OF LUNG CANCER |
Maria Werner-Wasik, M.D. |
| PHASE I/II CLINICAL EFFECTS OF C225, A CHIMERIZED
ANTIBODY TO THE EGF RECEPTORS IN HEAD AND NECK SQUAMOUS CELLS
CARCINOMA |
Harlan W. Waksal, M.D. |
| MODIFIED BIOCHEMOTHERAPY IN STAGE IV MELANOMA |
Rene Gonzalez, M.D. |
| STUDIES WITH THE MULTITARGETED ANTIFOLATE
LY231514 & GEMCITABINE IN ADVANCED SOLID TUMORS |
Alex A. Adjei, M.D. |
| ALLOVECTIN & LEUVECTIN GENE-BASED
IMMUNOTHERAPY |
Evan M. Hersh, M.D. |
| LIPOSOME ENCAPSULATED PACLITAXEL |
Joseph Treat, M.D. |
| CURRENT TREATMENT MODIFICATIONS IN MYELOMA |
Sundar Jagannath, M.D. |
NEWS ALERT! LATE-BREAKING DEVELOPMENTS IN CANCER THERAPY |
Ezra M. Greenspan, M.D.
Janice Gabrilove, M.D.
Edward P. Ambinder, M.D. |
| STUDIES WITH ECTEINASCIDIN-743
(ET-743), A MARINE ALKALOID |
David P. Ryan, M.D. |
| BDH-4556-TROXACITABINE, A NOVEL
NUCLEOSIDE ANALOG AS AN ANTILEUKEMIA AGENT |
Francis J. Giles, M.D. |
| STEM CELL RESCUE AFTER BONE MARROW
CURETTAGE FOR MYELOFIBROSIS WITH MYELOIDMETAPLASIA |
Richard Silver, M.D. |
| THEOPHYLLINE, PENTOSTATIN AND
CHLORAMBUCILIN: PATIENTS WITH RELAPSED LYMPHOPROLIFERATIVE DISORDERS |
John C. Byrd, M.D. |
Breakfast Presentation D:
| NEW FRONTIERS IN TREATMENT OF
COLORECTAL CANCER |
John L. Marshall, M.D. |
| CHALLENGES AND ADVANCES IN THE TREATMENT OF
BREAST CANCER |
John C. Gutheil, M.D. |
-Return
to Product Page- |
